About this episode
Blood-based Biomarkers, Anti-Amyloid Therapies and BeyondFrom blood-based biomarkers to anti-amyloid treatments, join us as we explore the latest in Alzheimer’s disease diagnosis and treatment with Dr. Halima Amjad. This episode will equip you to guide your patients about the latest Alzheimer’s diagnostics as well as eligibility, risks and monitoring for anti-amyloid therapies.Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMEShow Segments
Intro
Case
Cognitive and functional history reminders
Diagnosing Alzheimer’s Disease
Blood-based biomarkers
Anti-amyloid therapy indications, eligibility and contraindications
Patient counseling and treatment decisions
ARIA
Key takeaways
Outro
Credits
Written and Produced by: Natalie Barrett DO, Rachel K Miller MD
Show notes, cover art and infographic: Natalie Barrett DO, Rachel K Miller MD, Leah Witt MD
Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP
Reviewer: Sai S Achi MD, MBA,FACP
Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP
Technical Production: PodPaste
Guest: Halima Amjad, MD
DisclosuresDr. Amjad reports financial relationships with Centene (Advisor) and Craniometrix (Advisor). Relationships have not ended. The Curbsiders report no relevant financial disclosures. The production of this episode was supported by the Penn Geriatrics AGE-SMART Geriatric Workforce Enhancement Grant. This podcast content is solely the responsibility of the authors and does not necessarily represent the official views of the Health Resources and Services Administration or the U.S. Department of Health and Human Services. Sponsor: Babbel Right now get up to 55% off your Babbel subscription at Babbel.com/CURB.Sponsor: QuinceGo to
